<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023733</url>
  </required_header>
  <id_info>
    <org_study_id>HHC-2020-0243</org_study_id>
    <nct_id>NCT05023733</nct_id>
  </id_info>
  <brief_title>Clinical and Radiographic Outcomes of TLIF w/3D Printed Cellular Implant</brief_title>
  <official_title>Clinical and Radiographic Outcomes of Transforaminal Lumbar Interbody Fusion (TLIF) With a Novel 3D Printed Cellular Titanium Implant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Farhan Karim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DePuy Synthes</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hartford Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate clinical outcomes and spine fusion rates for patients&#xD;
      undergoing transforaminal lumbar interbody fusion using the CONDUIT 3D printed titanium TLIF&#xD;
      cage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, single-center study is being conducted as a post market evaluation of the&#xD;
      CONDUIT 3D printed titanium TLIF Cage. Patients undergoing transforaminal lumbar interbody&#xD;
      fusions due to lumbar spinal pathology (i.e. central foraminal stenosis, degenerative disc&#xD;
      disease, and/or lumbar spondylolisthesis) and have failed conservative care will be recruited&#xD;
      for this study. Patients will be serially evaluated at 6 month intervals for a total of 24&#xD;
      months post index procedure to assess patient reported outcomes, clinical outcomes, and&#xD;
      radiographic parameter, specifically spine fusion rates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic Fusion</measure>
    <time_frame>18 months</time_frame>
    <description>Fusion success measured by radiological assessment. Evidence of fusion demonstrated by bone formation through the cage on anteroposterior (AP) and Lateral radiographs, Flexion and Extension radiographs at 18 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic Fusion</measure>
    <time_frame>24 months</time_frame>
    <description>Fusion success measured by radiological assessment. Evidence of fusion demonstrated by bone formation through the cage on anteroposterior (AP) and Lateral radiographs, Flexion and Extension radiographs at 24 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Back and Leg Visual Analog Scale (VAS)</measure>
    <time_frame>6 months</time_frame>
    <description>Improvement in the VAS as measured by a minimum of a 20 point improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Back and Leg Visual Analog Scale (VAS)</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement in the VAS as measured by a minimum of a 20 point improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Back and Leg Visual Analog Scale</measure>
    <time_frame>18 months</time_frame>
    <description>Improvement in the VAS as measured by a minimum of a 20 point improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index (ODI)</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical Improvement will be defined by improvement in Oswestry Disability Index (ODI) &gt;20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index (ODI)</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical Improvement will be defined by improvement in Oswestry Disability Index (ODI) &gt;20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index (ODI)</measure>
    <time_frame>18 months</time_frame>
    <description>Clinical Improvement will be defined by improvement in Oswestry Disability Index (ODI) &gt;20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Number of procedure and device related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention Rates</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Rates of reoperation and/or revision procedures at index level(s)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Foraminal Stenosis</condition>
  <condition>Degenerative Disc Disease</condition>
  <condition>Lumbar Spondylolisthesis</condition>
  <condition>Lumbar Spinal Stenosis</condition>
  <arm_group>
    <arm_group_label>1-2 contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1</arm_group_label>
    <description>One to two contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1 whose condition requires the use of interbody fusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CONDUIT™ Interbody Platform composed of the EIT (Emerging Implant Technologies) Cellular Titanium®</intervention_name>
    <description>Patients undergoing 1-2 contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1</description>
    <arm_group_label>1-2 contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1</arm_group_label>
    <other_name>lumbar fusion</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be skeletally mature adults ages 35-80 years of age undergoing one or two&#xD;
        level transforaminal lumbar interbody fusion. These patients will have a diagnosis of&#xD;
        lumbar degenerative disc disease with or without neurologic deficit and associated central&#xD;
        and/or unilateral /bilateral foraminal stenosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Skeletally mature adults ages 35 - 80 years of age, inclusive&#xD;
&#xD;
          -  Diagnosis of lumbar degenerative disc disease with or without neurologic deficit and&#xD;
             associated central and/or unilateral/bilateral foraminal stenosis&#xD;
&#xD;
          -  Subject undergoing one or two level transforaminal lumbar interbody fusion&#xD;
&#xD;
          -  Able to read and understand all documents used in this study , including the informed&#xD;
             consent and patient-reported outcome questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients over 80 years of age&#xD;
&#xD;
          -  Patients under 35 years of age&#xD;
&#xD;
          -  Current smokers&#xD;
&#xD;
          -  BMI&gt;42&#xD;
&#xD;
          -  Subject has spondylolisthesis &gt; 2&#xD;
&#xD;
          -  Subjects with multilevel &gt;2 levels of symptomatic disease&#xD;
&#xD;
          -  Subjects with significant spinal deformity&#xD;
&#xD;
          -  Subject is pregnant, plans to become pregnant or is breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhan Karim, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartford Hospital; Hartford Healthcare Bone &amp; Joint Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bethany Samperi</last_name>
    <phone>860-972-5978</phone>
    <email>bethany.samperi@hhchealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew Solomito, PhD</last_name>
    <phone>203-525-7659</phone>
    <email>matthew.solomito@hhchealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hartford Healthcare Bone and Joint Institute</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bethany Samperi</last_name>
      <phone>860-972-5978</phone>
      <email>bethany.samperi@hhchealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Matthew Solomito, PhD</last_name>
      <phone>203-525-7659</phone>
      <email>matthew.solomito@hhchealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Farhan Karim, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hartford Hospital</investigator_affiliation>
    <investigator_full_name>Farhan Karim</investigator_full_name>
    <investigator_title>Spine Surgeon</investigator_title>
  </responsible_party>
  <keyword>transforaminal</keyword>
  <keyword>degenerative disc disease (DDD)</keyword>
  <keyword>Lumbar Fusion</keyword>
  <keyword>Interbody Fusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

